PDF herunterladen
Thromb Haemost 2007; 98(06): 1384-1386
DOI: 10.1160/TH07-06-0394
Letters to the Editor
Schattauer GmbH

Once-daily fondaparinux monotherapy without warfarin for long-term treatment of venous thromboembolism

Ranjith Shetty
1   Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
,
Ali Seddighzadeh
1   Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
,
Sudha Parasuraman
1   Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
2   Division of Hematology-Oncology, Children’s Hospital, Boston, Massachusetts, USA
,
Neelima G. Vallurupalli
3   Cardiovascular Division, Baystate Medical Center, Tufts Medical School, Springfield, Massachusetts, USA
,
Marie Gerhard Herman
1   Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
,
Samuel Z. Goldhaber
1   Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
› Institutsangaben Financial support: This study was funded by GlaxoSmithKline. ClinicalTrials.gov Identifier: NCT00413504
Weitere Informationen

Publikationsverlauf

Received 06. Juni 2007

Accepted after resubmission 01. November 2007

Publikationsdatum:
15. Dezember 2017 (online)

    Lizenzen und Reprints

 

 

  • References

  • 1 Petitou M, Duchaussoy P, Herbert JM. et al. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Semin Thromb Hemost 2002; 28: 393-402.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 2 Sankoh AJ, Huque MF, Dubey SD. Some comments on frequently used multiple endpoint adjustments methods in clinical trials. Statistics Med 1997; 16: 2529-2542.
    CrossrefPubMedGoogle Scholar
  • 3 Beckman JA, Dunn K, Sasahara AA. et al. Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thromb Haemost 2003; 89: 953-958.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 4 Kucher N, Quiroz R, Mckean S. et al. Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vascular Med 2005; 10: 251-256.
    PubMedGoogle Scholar
  • 5 Hull RD, Pineo GF, Brant RF. et al. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 2007; 120: 72-82.
    CrossrefPubMedGoogle Scholar
  • 6 Buller HR, Davidson BL, Decousus H. et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695-1702.
    CrossrefPubMedGoogle Scholar
  • 7 Buller HR, Davidson BL, Decousus H. et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140: 867-873.
    CrossrefPubMedGoogle Scholar
  • 8 Wittkowsky AK, Downing J, Blackburn J. et al. Warfarin-related outcome in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic. Thromb Haemost 2006; 96: 137-141.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 9 Arixtra Dosing and Administration.. GlaxoSmith- Kline. Available at: http://www.arixtra.com/dosing.htm . Accessed March 12, 2007.
    PubMedGoogle Scholar